Summary of Nurix Therapeutics FY Conference Call Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Date**: September 10, 2025 - **Key Speaker**: Arthur T. Sands, President and CEO Core Industry and Company Insights Pipeline and Programs - Nurix is entering pivotal studies for its lead program, Bexobrutide (BexDeg), targeting chronic lymphocytic leukemia (CLL) [2] - The company is planning Phase 2 and 3 studies for BexDeg, with recent design considerations disclosed for the Phase 3 study [2][20] - Other programs include NX-2127 and NX-1607, focusing on aggressive lymphomas and immuno-oncology targets, respectively [2][3] - The company has a partnership with Sanofi for a STAT6 degrader and with Gilead for an IRAK4 degrader, both in IND-enabling studies [3][54] Platform and Technology - Nurix's platform is based on E3 ligases and has evolved to include a DEL-AI platform for ligand discovery, allowing for rapid development across oncology and inflammation [5][6] - The platform enables the development of degrader antibody conjugates (DACs), with a partnership with Pfizer [7] Safety and Efficacy of BexDeg - BexDeg has shown no drug-related atrial fibrillation above background levels, indicating a favorable cardiovascular profile compared to other BTK inhibitors [18] - The design of BexDeg aims for high selectivity and potency, which is expected to translate into better efficacy and safety [14] Pivotal Trial Design - The pivotal trial for BexDeg includes a single-arm study for accelerated approval in a third-line plus population, with a randomized control trial planned as a confirmatory study [20][21] - Key endpoints for the accelerated approval include overall response rate (ORR) and progression-free survival (PFS), with an observed ORR of about 80% in earlier trials [22][23] - The market opportunity for the third-line plus patient population is estimated to be between 8,000 to 10,000 patients in the U.S., with significant revenue potential [25] Future Aspirations - Nurix is considering combination therapies for earlier lines of treatment, with plans for a Phase 1B/2 study combining BexDeg with venetoclax and anti-CD20 antibodies [36] - The company is currently self-funding its studies but is open to partnerships for future combination studies [38] Financial Position - Nurix has a cash runway extending into the first half of 2027, with approximately $485 million in cash as of the last quarter [61] Additional Insights - The company is actively participating in upcoming medical conferences to present data on its various programs, including ESMO and ASH [42][45] - The STAT6 program with Sanofi is expected to enter healthy volunteer studies by 2026, pending Sanofi's timeline [56] This summary encapsulates the key points discussed during the conference call, highlighting Nurix Therapeutics' strategic priorities, pipeline developments, and market opportunities.